Mobile

A 4-week trial evaluating the efficacy, safety, and tolerability of GRT6005, a new centrally acting analgesic, in subjects with moderate to severe pain due to osteoarthritis of the knee

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-022556-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To explore the analgesic efficacy of fixed doses of 75 µg, 200 µg, and 400 µg GRT6005 once daily compared to placebo in subjects with moderate to severe pain due to OA of the knee.

Critère d'inclusion

  • Pain due to Osteoarthritis of the knee

Liens